Romosozumab
Romosozumab
Romosozumab (pronunciation: roe-moe-soe-ZUE-mab) is a monoclonal antibody medication used for the treatment of osteoporosis in postmenopausal women who are at high risk of fracture.
Etymology
The name Romosozumab is derived from the combination of the words "Romo", which is an abbreviation for the company that developed the drug, Amgen (formerly known as Roche Molecular Systems), and "sozumab", a common suffix for monoclonal antibodies.
Usage
Romosozumab is used to treat osteoporosis in postmenopausal women who are at high risk of fracture. It works by increasing bone formation and decreasing bone resorption, which can lead to an overall increase in bone mineral density.
Mechanism of Action
Romosozumab works by binding to and inhibiting sclerostin, a protein that inhibits bone formation. By inhibiting sclerostin, romosozumab allows for increased bone formation and decreased bone resorption.
Side Effects
Common side effects of Romosozumab include joint pain, headache, and injection site reactions. Serious side effects may include hypocalcemia, osteonecrosis of the jaw, and atypical femoral fractures.
Related Terms
- Monoclonal antibody
- Osteoporosis
- Sclerostin
- Bone resorption
- Bone formation
- Hypocalcemia
- Osteonecrosis
- Atypical femoral fractures
External links
- Medical encyclopedia article on Romosozumab
- Wikipedia's article - Romosozumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski